Read More

Sangamo Therapeutics’s Earnings Outlook

Sangamo Therapeutics (NASDAQ:SGMO) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Sangamo Therapeutics will report an earnings per share (EPS) of $-0.35.

SGMO

Read More

Sangamo Therapeutics Announced Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Nine Patients

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) today announced updated preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease.

SGMO